Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib for Recurrent and Metastatic Primary Malignant Bone Tumors
NCT03527888Phase 2Unknown
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Jan 2018
- Primary completion
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of anlotinib in osteosarcoma (OS), chondrosarcoma, undifferentiated pleomorphic sarcoma (UPS), Malignant Fibrous Histiocytoma (MFH), Giant Cell Tumor of Bone (GCTB), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Status: unknown.
02
Drugs
anlotinib
03
Conditions
osteosarcoma (OS)chondrosarcomaundifferentiated pleomorphic sarcoma (UPS)Malignant Fibrous Histiocytoma (MFH)Giant Cell Tumor of Bone (GCTB)
Beyond the preview
Go deeper on NCT03527888.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03527888.